Join Davida Kruger, NP and Anne Peters, MD for a lively discussion on the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in clinical practice, including how to use shared decision-making to choose an ideal agent based on patient, disease, and GLP-1 RA characteristics. The unique effects of GLP-1 RAs on cardiovascular disease and weight mitigation are also discussed in the context of patient selection and management.
After completing this activity, participants should be better able to:
- Incorporate a patient-centered approach into management of patients with type 2 diabetes to help address patient social, emotional, and health factors
- Identify the appropriate use of GLP-1 RA therapy based on cardiovascular risk and patient needs, preferences, and abilities
NPs and PAs
Joint Accreditation Statement
In support of improving patient care, Practicing Clinicians Exchange is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
ANCC Credit Designation
Nursing contact hours: 0.25, which includes 0.25 hours of pharmacology credit
AAPA Credit Designation
Practicing Clinicians Exchange has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid until March 25, 2022. PAs should only claim credit commensurate with the extent of their participation.
IPCE Credit Designation
This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.
This activity is supported by an educational grant from Novo Nordisk Inc.
The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.
All faculty and planners participating in continuing education activities sponsored by Practicing Clinicians Exchange (PCE) are required to disclose all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to PCE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.
Ms Kruger: advisory board: Eli Lilly and Company, Merck, Sanofi-Aventis; advisory board/research support/speakers bureau: Abbott, Dexcom, Novo Nordisk; advisory board/speakers bureau: BI-Lilly, Janssen; advisory board/stock: Pendulum Therapeutics; research support: The Leona M. and Harry B. Helmsley Charitable Trust, Lexicon Pharmaceuticals; speakers bureau: AstraZeneca, Insulet, Lilly, Valeritas.
Dr Peters: advisory board: Abbott Diabetes Care, Bio-Rad, Eli Lilly and Company, MannKind, Medscape, Merck, Novo Nordisk, Zealand; advisory board/stock: Omada Health, Pendulum Therapeutics, Stability Health, Teladoc; research support: Abbott Diabetes Care, Dexcom, vTv Therapeutics.
None of the members of the PCE staff have any relevant relationships to disclose.
Participants wishing to earn CE/CME credit must:
- Listen to the content in its entirety
- Relate the content material to the learning objectives
- Complete the post-test and evaluation form
Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of 100%.
The estimated time to complete this activity is 0.25 hours.
Release date: March 26, 2021
Expiration date: March 25, 2022
© 2021 Practicing Clinicians Exchange. All Rights Reserved. 101020N-1